<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00675194</url>
  </required_header>
  <id_info>
    <org_study_id>GC-ICE-2003</org_study_id>
    <nct_id>NCT00675194</nct_id>
  </id_info>
  <brief_title>Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer</brief_title>
  <official_title>A Prospective, Open, Comparative Multicentre Phase II Study for the Evaluation of Irinotecan and Capecitabine Versus Cisplatin and Capecitabine in Advanced Gastric Adenocarcinoma or Gastric-Oesophagal Junction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which Arm (capecitabine + irinotecan versus
      capecitabine + cisplatin) shows higher response rates in the treatment of advanced
      gastric-oesophagal cancer

      Furthermore, comparison of progression-free survival, 1-year survival, Quality of Life and
      safety
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      capecitabine + irinotecan versus capecitabine + cisplatin, as published by Kang et al. (ASCO
      2006)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the dose and efficacy of Epoetin beta weekly in anaemic patients</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin, Irinotecan, Capecitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  gastric or gastric-oesophagal junction adenocarcinoma

          -  unidimensional measurable disease

          -  Karnofsky index &gt;/=60%

        Exclusion Criteria:

          -  prior chemo- or radiotherapy

          -  colorectal diseases

          -  brain metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Moehler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johannes Gutenberg University Mainz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johannes Gutenberg Universit√§t , I. Medizinische Klinik und Polokilinik</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2008</study_first_posted>
  <last_update_submitted>May 16, 2008</last_update_submitted>
  <last_update_submitted_qc>May 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2008</last_update_posted>
  <keyword>cisplatin</keyword>
  <keyword>capecitabine</keyword>
  <keyword>gastric</keyword>
  <keyword>irinotecan</keyword>
  <keyword>metastatic</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

